These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34094921)

  • 1. Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-
    Bai X; Dai J; Li C; Cui C; Mao L; Wei X; Sheng X; Chi Z; Yan X; Tang B; Lian B; Wang X; Zhou L; Li S; Kong Y; Qi Z; Xu H; Duan R; Guo J; Si L
    Front Oncol; 2021; 11():639085. PubMed ID: 34094921
    [No Abstract]   [Full Text] [Related]  

  • 2. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy.
    Pozorski V; Park Y; Mohamoud Y; Tesfamichael D; Emamekhoo H; Birbrair A; Albertini MR; Ma VT
    Pigment Cell Melanoma Res; 2023 Nov; 36(6):501-511. PubMed ID: 37903733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy.
    Bartlett EK; Flynn JR; Panageas KS; Ferraro RA; Sta Cruz JM; Postow MA; Coit DG; Ariyan CE
    Cancer; 2020 Jan; 126(1):76-85. PubMed ID: 31584709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population.
    Qi Y; Liao D; Mei D; Zhang Y; Liu Y
    Front Oncol; 2020; 10():1752. PubMed ID: 33042821
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1.
    Janka EA; Ványai B; Szabó IL; Toka-Farkas T; Várvölgyi T; Kapitány A; Szegedi A; Emri G
    Front Oncol; 2023; 13():1237643. PubMed ID: 37664072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.
    Soyano AE; Dholaria B; Marin-Acevedo JA; Diehl N; Hodge D; Luo Y; Manochakian R; Chumsri S; Adjei A; Knutson KL; Lou Y
    J Immunother Cancer; 2018 Nov; 6(1):129. PubMed ID: 30470260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 9. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
    Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
    EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy.
    Dercle L; Ammari S; Roblin E; Bigorgne A; Champiat S; Taihi L; Plaian A; Hans S; Lakiss S; Tselikas L; Rouanne M; Deutsch E; Schwartz LH; Gönen M; Flynn J; Massard C; Soria JC; Robert C; Marabelle A
    Eur J Cancer; 2022 Dec; 177():80-93. PubMed ID: 36332438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators.
    Byun HK; Chang JS; Jung M; Koom WS; Chung KY; Oh BH; Roh MR; Kim KH; Lee CK; Shin SJ
    Front Oncol; 2021; 11():659754. PubMed ID: 34123816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
    Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
    Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
    Ferrucci PF; Ascierto PA; Pigozzo J; Del Vecchio M; Maio M; Antonini Cappellini GC; Guidoboni M; Queirolo P; Savoia P; Mandalà M; Simeone E; Valpione S; Altomonte M; Spagnolo F; Cocorocchio E; Gandini S; Giannarelli D; Martinoli C
    Ann Oncol; 2016 Apr; 27(4):732-8. PubMed ID: 26802161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1-Based Therapy.
    Li H; An X; Huang R; Li L; Chu C; Yang W; Qin Z; Liu Z; Zhou F; Xue C; Shi Y
    Front Mol Biosci; 2021; 8():621883. PubMed ID: 34458319
    [No Abstract]   [Full Text] [Related]  

  • 16. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
    Banna GL; Signorelli D; Metro G; Galetta D; De Toma A; Cantale O; Banini M; Friedlaender A; Pizzutillo P; Garassino MC; Addeo A
    Transl Lung Cancer Res; 2020 Aug; 9(4):1533-1542. PubMed ID: 32953525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy.
    He LN; Zhang X; Li H; Chen T; Chen C; Zhou Y; Lin Z; Du W; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
    Front Oncol; 2020; 10():621329. PubMed ID: 33552993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A composite indicator of derived neutrophil-lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors.
    Chen S; Guo S; Gou M; Pan Y; Fan M; Zhang N; Tan Z; Dai G
    Front Oncol; 2022; 12():951985. PubMed ID: 36387152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy.
    Kött J; Hoehne IL; Heidrich I; Zimmermann N; Reese KL; Zell T; Geidel G; Rünger A; Schneider SW; Pantel K; Smit DJ; Gebhardt C
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.